JM-012: candidate for morning akinesia in Parkinson’s disease patients

  • L-dopa, a widely-used drug for Parkinson’s disease, is known to be effective for improving symptoms of the disease. However, in order to maintain such effect, plasma concentration of L-dopa must also be continously controlled.


  • Morning akinesia occurs after a Parkinson’s disease patient wakes up in the morning and before the efficacy of the first dose of L-dopa appears. Up to 50% of Parkinson’s disease patients who have taken L-dopa for several years are known to experience morning akinesia. This condition has debilitating influence on everyday activities such as waking up in the morning, putting clothes on, washing one’s body and preparing breakfast, thereby seriously affecting the patients’ quality of life. However, there is no appropriate treatment for this condition.


  • JM-012 is a special formulation under development to control absorption of L-dopa. If the formulation is successfully completed, it will prevent and treat morning akinesia, by exerting effects similar to that resulting from taking L-dopa at dawn.


  • JM-012 is under joint development by Bukwang’s subsidiary Contera Pharma, a Danish formulation specialist company Solural, Ernst Moritz Arndt University Greifswald in Germany, and Erweka. The project was selected to receive Eurostar grant, which is awarded to new drug projects in Europe, in June 2015.




|    ​Korean    |